We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Slaps Foghorn With Another Clinical Hold on its Anticancer Line
FDA Slaps Foghorn With Another Clinical Hold on its Anticancer Line
The FDA has placed a partial clinical hold on Foghorn Therapeutics’ phase 1 dose-escalation study of FHD-609 after a patient with synovial sarcoma developed a serious heart arrythmia while taking the second-highest dose.